Health equity is crucial to ensuring that all individuals have access to essential care.
The COVID-19 pandemic demonstrated how some groups, such as Black, Asian, and minority ethnic (BAME) communities, and those living in deprived areas, were disproportionately affected by the virus. However, while COVID-19 drew attention to these healthcare disparities, they have existed for decades.
In recent times, regulatory bodies have put tackling health inequities at the front line of their agendas, recognizing the crucial role real-world data (RWD) play in answering the questions that help us understand and reverse current and future health inequity, and expanding the reach of new technologies to underserved patient populations.
At CorEvitas, part of Thermo Fisher Scientific, we are committed to working hand in hand with our partners to generate high-quality, fit-for-purpose real-world evidence (RWE) that not only recognizes and accounts for health inequities in development and assessment, but also quantifies its impact on healthcare outcomes. Together, we can create a more equitable healthcare system that ensures access to essential care and a deeper understanding of the many factors associated with the costs of disease for all individuals, regardless of their background or circumstances.
Click to browse our resources and discover how our work supports health equity.